Introduction
Bipolar disorder is a potentially lifelong and disabling condition characterized by episodes of mania or hypomania and episodes of depressed mood (Grunze et al., 2013; Kendall et al., 2014) . Bipolar disorder is associated with an excess mortality including an increased risk of suicide (Grunze et al., 2013; Kendall et al., 2014 ). An estimated 25% to 50% of patients with bipolar disorder Table 1 Table 1 . Continued are reported to attempt suicide at least once (Jamison, 2000) . A recent network meta-analysis showed that adherence to pharmacological treatment is critical for effective control of depressive and manic symptoms (Miura et al., 2014) . Thus, adherence to medication is essential for people with bipolar disorder to respond satisfactorily to the treatment (Grunze et al., 2013; Kendall et al., 2014) . However, adherence to pharmacotherapy is often poor in chronic psychiatric illnesses, including bipolar disorder (Anderson et al., 2012; Geddes and Miklowitz, 2013; Zullig et al., 2013) . The frequency of nonadherence in bipolar disorder patients is estimated to range between 10% and 60% (Gigante et al., 2012) . Nonadherence increases the risk of relapse and suicide (Samalin et al., 2014) as well as risk of rehospitalization (Gigante et al., 2012) . Long-acting injectable (LAI) antipsychotics (LAI-APs) are considered to possess several benefits compared with oral antipsychotics, including more stable blood levels, consistent bioavailability, predictable medication adherence, and an improved pharmacokinetic profile, all of which allow for use of lower dosages (Spanarello and La Ferla, 2014) . Consequently, the LAI-APs are expected to have greater relapse prevention for psychiatric disorders including bipolar disorder and schizophrenia (Grunze et al., 2013; Priebe et al., 2013; Yatham et al., 2013; Kendall et al., 2014; NICE, 2014) and reduce the incidence of adverse events (Spanarello and La Ferla, 2014) in comparison with oral antipsychotics. In light of the recent network meta-analysis of bipolar disorder indicating that continuous antipsychotic treatment is effective for preventing relapse (Miura et al., 2014) , we hypothesized that LAI-APs are superior to oral medications, including oral antipsychotic and mood stabilizers, regarding efficacy. In fact, the United States Food and Drug Administration approved the use of risperidone-LAI as both monotherapy and adjunct therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in 2009. To date, 7 randomized controlled trials (RCTs) have been conducted on LAI-APs for the treatment of bipolar disorder (Ahlfors et al., 1981; Yatham et al., 2007; Macfadden et al., 2009; Chengappa et al., 2010; Quiroz et al., 2010; Bobo et al., 2011; Vieta et al., 2012) . However, although the results of a systematic review and meta-analyses are considered to present a higher level of evidence than individual trials (Higgins and Green, 2011) , there has been no systematic review and metaanalysis of LAI-APs regarding efficacy, tolerability, or safety for patients with bipolar disorder. A meta-analysis can increase the statistical power for group comparisons and overcome the limitation of sample size in underpowered studies (Higgins and Green, 2011) . To synthesize the available trial evidence, we conducted a systematic review and meta-analysis of RCTs comparing LAI-APs to placebo and oral medications for bipolar disorder. The meta-analysis was designed to assess the benefits and drawbacks of LAI-APs by comparing efficacy, discontinuation rates, and adverse events to placebo and oral medication groups.
METHODS
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Moher et al., 2009 ) (supplementary Table 1 : PRISMA Checklist).
Search Strategy and Inclusion Criteria of Studies
To identify relevant RCTs, 2 authors (T.K. and K.O.) independently searched MEDLINE, Cochrane Library, and PsycINFO, without language restrictions, from inception to March 26, 2016 using the following search strategy: (bipolar disorder, mania, manic, hypomania, hypo-mania, rapid cycle, rapidcycle, or bipolar depression) AND (randomized, random, or randomly) AND (depot, decanoate, enanthate, long acting injectable, microsphere, once monthly, palmitate, or pamoate). Two authors (T.K. and K.O.) independently assessed inclusion/exclusion criteria and selected studies. The references of included articles and review articles were also searched for citations of additional relevant published and unpublished research, such as conference abstracts. We also searched the clinical trial registries (ClinicalTrials.gov; http://clinicaltrials.gov/) and WHO International Clinical Trials Registry Platform (http://www.who. int/ictrp/search/en/) to include RCTs as comprehensively as possible and to minimize the possibility of publication bias.
Data Synthesis and Outcome Measures
The primary outcome was study-defined relapse rate of any mood symptom (supplementary Table 2 ). Secondary outcome measures were study-defined relapse rate of manic/hypomanic/ mixed symptoms or depressive symptoms, number of episodes (any mood symptoms, manic/hypomanic/mixed symptoms, or depressive symptoms) (supplementary Table 2 ), score on the Young Mania Rating Scale (Young et al., 1978) , MontgomeryÅsberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) , or Clinical Global Impression-Severity (CGI-S) scale (Guy and Bonato, 1970) at the study endpoint, discontinuation rates, and individual adverse events.
Data Extraction
Two authors (T.K. and K.O.) independently extracted data from the included studies. We used intention-to-treat or modified intention-to-treat analysis. When data required for the metaanalysis were missing, we contacted the study investigators and requested unpublished data. The following 2 categorical metaanalyses of RCTs were performed for evaluating each outcome: (1) risperidone-LAI vs the placebo, and (2) individual and pooled LAI-APs vs oral medications, including oral antipsychotics, mood stabilizers, antidepressants, or any combination of these agents.
Meta-Analytic Methods
These meta-analyses were conducted using Review Manager Software (Version 5.3 for Windows, Cochrane Collaboration, http://tech.cochrane.org/Revman). The random effects model was chosen because of potential heterogeneity across studies. The risk ratio (RR) was estimated along with its 95% CI for each meta-analysis. In this study, when the RR showed significant differences between groups for efficacy or adverse events, the number needed to treat or harm (NNT or NNH) was calculated from the risk difference (RD) using the formula NNT = 1/ RD or NNH = 1/RD. For continuous data, weighted mean differences (WMDs) were used. When outcomes with different metrics were combined, standardized mean differences were used (DerSimonian and Laird, 1986) . We also planned to investigate study heterogeneity using the chi-square test of homogeneity (P < .05) together with the I 2 statistic, considering I 2 ≥ 50% indicative of considerable heterogeneity (Higgins et al., 2003) . In cases with I 2 ≥ 50% for the primary outcome, we performed sensitivity analyses to determine the reasons for the heterogeneity. We also assessed the methodological qualities of the articles included according to the Cochrane Risk of Bias Criteria (Cochrane Collaboration, http://www.cochrane.org/).
RESULTS

Study Characteristics
Of 198 hits, we removed 151 duplicates, 33 references based on abstract/title review, and 7 articles after full-text review (6 review articles and 1 same study), retaining 7 RCTs (Ahlfors et al., 1981; Yatham et al., 2007; Macfadden et al., 2009; Chengappa et al., 2010; Quiroz et al., 2010; Bobo et al., 2011; Vieta et al., 2012 ) (supplementary Figure 1) . Moreover, we did not retrieve any additional RCTs by searching the review articles and the clinical trial registries. Thus, the meta-analysis included 7 RCTs (n = 1016; LAI-APs [flupenthixol and risperidone, 449]; oral medication [mood stabilizers, antidepressants, antipsychotic, or any combination of these agents, 283]; and placebo, 284). The details of each study are described in Table 1 . One trial tested flupenthixol decanoate (25 subjects) (Ahlfors et al., 1981) and 6 tested risperidone-LAI (424 subjects). Four of the 7 RCTs examined risperidone-LAI added to usual treatments (mood stabilizers, antidepressants, antipsychotics, or any combination of these agents). As the comparator group, 2 studies used various oral second-generation antipsychotics (SGAs, 51 subjects) (Yatham et al., 2007; Chengappa et al., 2010) and 1 used olanzapine (131 subjects) (Vieta et al., 2012) . Both the mean and median duration of studies was 15 months. Two of the 7 RCTs included only patients with rapid cycling (Bobo et al., 2011) or high frequency of relapse (Macfadden et al., 2009) (Table 1 ). All 7 RCTs were industry sponsored. Three of the 7 RCTs were double blind. The methodological quality of each RCT based on Cochrane risk-of-bias criteria are shown in supplementary Figures 2 and 3. 
LAI-APs vs Placebo
Risperidone-LAI outperformed the placebo regarding the primary outcome, study-defined relapse rate of any mood symptom (RR = 0.63, 95% CI = 0.51 to 0.77, P < .0001, I 2 = 13%, NNT = −5, P < .00001, N = 2, n = 567) (Figure 1 ). Risperidone-LAI was also superior to the placebo in study-defined relapse rate for manic, hypomanic, or mixed symptoms (RR = 0.42, 95% CI = 0.29 to 0.61, P < .00001, I 2 = 38%, NNT = −4, P < .00001, N = 2, n = 537, Figure 2 ), and improved scores on the Young Mania Rating Scale (WMD = −5.80, 95% CI = −7.57 to −4.04, P < .00001, I 2 = 0%, N = 2, n = 532), MADRS (WMD = −1.76, 95% CI = −3.23 to −0.28, P = .02, I 2 = 0%, N = 2, n = 532), and CGI-S scale (WMD = −0.76, 95% CI = −1.03 to −0.50, P < .00001, I 2 = 0%, N = 2, n = 532). In contrast, the risperidone-LAI arm did not differ from the placebo in study-defined relapse rate of depressive symptoms (Table 2) . While the meta-analyses of allcause discontinuation revealed a statistically significant superiority of risperidone-LAI over the placebo (RR = 0.75, P = .007, NNT = −5), there was no significant difference in discontinuation rate due to adverse events between groups (RR = 1.99, P = .33). Risperidone-LAI was associated with a lower incidence of mania (RR = 0.31, P = .001, NNH = −14) and use of benzodiazepines (RR = 0.54, p = 0.02, NNH = −17) compared with the placebo (Table 2 ). However, risperidone-LAI was associated with a higher incidence of potential prolactin-related adverse events (RR = 4.82, P = .001, NNH = not significant) and weight gain (≥7% increased) (RR = 3.80, P < .0001, NNH = 10) compared with the placebo (Table 2) .
LAI-APs vs Oral Medications
Neither pooled LAI-APs nor any single individual LAI-AP (flupenthixol or risperidone) differed from oral medications regarding the primary outcome and secondary efficacy outcomes (Figures 1 and 2 ; Table 3 ). There were also significant differences in discontinuation rate between the treatment groups (Table 3) . Risperidone-LAI was associated with a higher incidence of potential prolactin-related adverse events (RR = 2.66, P = .03, NNH = 20) compared with oral medications, but there were no significant differences in other individual adverse events between the groups (Table 3) .
Sensitivity Analyses of LAI-APs vs Oral Medications
Since we found significant heterogeneity in the primary outcome between treatment groups (I 2 = 74%) (Figure 1 ), we conducted sensitivity analyses in RCT subgroups divided by study duration (≥15 or <15 months), blinding (double blind or open), comparator (SGA monotherapy or other oral medications), type of bipolar disorder (rapid cycling or high frequency of relapse patients vs others), the LAI-AP tested (flupenthixol decanoate or risperidone-LAI), and sample size (total n > 100 or <100) ( Table 4) . Short duration studies (<15 months), open studies, studies with oral medications other than SGA monotherapy as the comparator, rapid cycling or high frequency of relapse patient studies, and small sample size studies (total n < 100) retained significant heterogeneity, but LAI-AP was superior to the placebo for prevention of study-defined relapse rate of any mood symptom (Table 4) . a Adverse events considered to be potentially prolactin-related (such as galactorrhea or libido decreased), as reported by the investigator.
*Number need to harm = −5, P = .006. **Number need to harm = not significant. ***Number need to harm = −14, P = .03. ****Number need to harm = −17, P = .02. *****Number need to harm = 10, P < .00001.
Discussion
This is the first meta-analysis of RCTs (7 studies, 1016 patients in total) examining the efficacy and safety of LAI-APs for bipolar disorder compared with placebo or oral medications. We found that risperidone-LAI was superior to the placebo in preventing relapse of any mood symptom (primary outcome) as well as for preventing manic symptoms, while relapse rate of depressive symptoms was similar to the placebo. Risperidone-LAI also improved MADRS score compared with the placebo, but the effect size was small (WMD = −1.76). Thus, results of this meta-analysis reveal a significant benefit of risperidone-LAI on symptom relapse, especially manic symptoms, compared with the placebo. Although relapse rate of any mood symptom pooled LAI-APs was similar to that on oral medications, LAIAPs was superior to oral medications in sensitivity analysis considering only studies of rapid cycling or high frequency of relapse patients. This result appears consistent with that of risperidone-LAI vs the placebo. Several studies reported that factors that have been associated with poor adherence include history of rapid cycling, bipolar type I disorder, and greater illness severity (Martinez-Aran et al., 2009; Perlis et al., 2010) . Other studies reported that poor adherence to medication has been associated with more manic symptoms (Sylvia et al., 2014) and a higher rate of recurrence and hospitalization (Hassan and Lage, 2009; Gutierrez-Rojas et al., 2010) but not with depressive symptoms (Sylvia et al., 2014) . We considered that LAI-APs might improve medication adherence and possibly reduce relapse in patients with these subtypes of bipolar disorder. However, the total number of patients in the sensitivity analysis was small (169 subjects from 2 Adverse events considered to be potentially prolactin-related (such as galactorrhea, menstrual changes or libido decreased), as reported by the investigator. *Number need to harm = 20, P = .01. the comparator of these 2 RCTs was not SGA monotherapy, and LAI-APs did not outperform SGA monotherapy regarding relapse rate in sensitivity analysis that included only studies that used SGA monotherapy as the comparator. Therefore, a RCT of LAI-AP vs SGA monotherapy for the treatment of rapid cycling or high frequency of relapse bipolar disorder patients is required. In addition, clinicians need to be aware of potential adverse events induced by risperidone-LAI, such as potential prolactin-related adverse events and weight gain. There are several limitations to the present analysis. First, we detected significant heterogeneity with respect to the primary outcome in the meta-analysis of LAI-APs vs oral medications, and sensitivity analyses did not identify the source. Additionally, although there were substantial differences in sample size among the studies included, the weighting of each was similar. Second, the total numbers of studies and patients included were relatively small. Since significant heterogeneity was detected, the limited sample size indicates that more research is needed to evaluate both the efficacy and tolerability of LAI-APs. Third, because a funnel plot is generally used only if 10 or more studies are included in the meta-analysis, we did not utilize this plot for exploring potential publication bias.
In conclusion, LAI-APs appear effective for relapse prevention in patients with rapid cycling. However, further RCTs of LAI-AP vs oral SGAs using larger sample sizes of rapid cycling patients are needed to definitively assess this potential benefit.
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